ASCO GI 2022 | Rationale behind combining a VEGF/Ang2-blocking nanobody and immunotherpay in advanced CRC

Susanna Varkey Ulahannan, MD, The University of Oklahoma College of Medicine, Oklahoma City, OK, explains the rationale behind using a bispecific nanobody targeting VEGF/ANG2 in combination with a PD-1 antibody in advanced colorectal cancer (CRC). VEGF and ANG2 have an immunosuppressive effect on the tumor microenvironment (TME). Therefore, anti-PD-1 would target the immunosuppression in addition to targeting angiogenesis. This interview took place at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2022.